United States

People: G1 Therapeutics Inc (GTHX.OQ)

GTHX.OQ on NASDAQ Stock Exchange Global Select Market

15 Feb 2019
Change (% chg)

$0.03 (+0.14%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Rudnick, Seth 

Dr. Seth A. Rudnick, M.D. is an Independent Chairman of the Board of G1 Therapeutics Inc. Dr. Rudnick is the Chairman of the Board of the Company. He has served as Chairman of our board of directors since May 2014 and as the Executive Chairman of our board of directors from January 2014 to May 2014. Dr. Rudnick also serves as a member of the boards of directors of several life sciences companies, including Pozen Inc., a publicly traded pharmaceutical company, and Liquidia Technologies, Inc., a privately held biotechnology company, for which he serves as Chairman of the board of directors. From 2012 until October 2015, he served as a member of the board of directors of Square 1 Financial Inc., a financial services company that was publicly traded until October 2015, and previously served on the boards of directors of more than a dozen other privately held biotechnology companies. From 1999 to December 2013, when he retired, Dr. Rudnick was a general partner at Canaan Partners, a venture capital firm that invests in companies in the technology and healthcare sectors. From 1986 to 1991, he was head of research and development at Johnson & Johnson’s biotechnology company, Ortho Biotech, and from 1982 to 1986, Dr. Rudnick was head of pharmaceutical development at Biogen N.V. Dr. Rudnick received a B.A. from the University of Pennsylvania and an M.D. from the University of Virginia. We believe that Dr. Rudnick is qualified to serve as the Chairman of our board of directors based on his experience in the life sciences, biotechnology and pharmaceutical industries and for his knowledge of corporate development matters.

Basic Compensation

Total Annual Compensation, USD 247,023
Restricted Stock Awards, USD --
Long-Term Incentive Plans, USD --
All Other, USD 10,500
Fiscal Year Total, USD 257,523

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Seth Rudnick


Mark Velleca


Barclay Phillips


Rajesh Malik


Terry Murdock


Jay Strum

As Of  30 Dec 2017